Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This source reports that clascoterone cream, a topical androgen receptor inhibitor, has shown effectiveness in treating facial acne vulgaris in patients 12 and older, with clinical trials indicating a favorable safety profile compared to systemic treatments, and potential for broader dermatological applications.

In this clinical trial, patients with lichen planopilaris treated with the oral TYK2 inhibitor deucravacitinib showed significant improvement in PGA, LPPAI, and Skindex-16 scores over 24 weeks, with transcriptomic analyses indicating decreased inflammatory and immune pathway activity post-treatment.

This study reported that the combination of a 308-nm excimer lamp and 10% liquor carbonis detergens significantly improved scalp psoriasis symptoms compared to the excimer lamp alone, with more patients achieving 75% reduction in their Psoriasis Scalp Severity Index.

In this case report, a 3-year-old male with IFAP syndrome showed moderate improvement in skin symptoms and corneal erosions but no change in alopecia or photophobia after 6 months of acitretin therapy.

This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.

This study reported improvement in hair loss lesions in C3H/HeJ mice with alopecia areata following treatment with the CCR5 inhibitor maraviroc, alongside reduced infiltration of specific T cells in the lesions.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This review discusses treatment strategies for alopecia areata, emphasizing current immunomodulation approaches but reports no new clinical results.

This article reviews the current status of oral retinoids in dermatology and reports no new clinical findings.

This study found that 3D imaging may serve as a promising tool for objectively evaluating facial vitiligo repigmentation after treatment with upadacitinib.

This article discusses the urgent issue of preserving freedom of choice in dermatology, highlighted by the American Academy of Dermatology, and reports no new research findings.

In this study, topical acyclovir significantly delayed hair growth initiation and completion in mice and reduced hair follicle size, suggesting potential inhibitory effects on hair growth.

This source summarizes the new 2024 American Academy of Dermatology guidelines, emphasizing strong recommendations for topical and oral therapies like benzoyl peroxide, doxycycline, and isotretinoin in managing acne vulgaris, while outlining the importance of tailored treatments for diverse patient needs in Canadian practice.

This review synthesizes current knowledge on acral vitiligo, highlighting its treatment resistance, psychosocial impact, and emerging therapies like JAK inhibitors, while identifying knowledge gaps and future research directions.

This case report details a middle-aged man with multiple sclerosis who developed difficult-to-evaluate skin reactions after daclizumab treatment, noting only slight improvement with additional therapies.

In this study, patients with active lymphocytic cicatricial alopecia showed significant improvement using a three-stage treatment regimen involving Tofacitinib, Apremilast, and Crisaborole, with 93.5% experiencing marked improvement and only three mild adverse events reported.

This study found that repetitive 532 nm laser therapy significantly decreased scores for macules, pigmented, and vascular lesions on the facial area, regardless of skin phototype or age.

This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.

Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.

This article in the International Journal of Dermatology reports on a case series where the drug upadacitinib was used to treat patients with recalcitrant lichen planopilaris, but no abstract or detailed results are provided to assess its efficacy or safety fully.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

This study reported that topical BPM31543 was safe and well-tolerated for patients on taxane-based chemotherapy, with some efficacy indicated in reducing hair loss at all dosages tested.

This study reported that a 10-week course of clindamycin and rifampicin was commonly used for treating folliculitis decalvans but the evidence on its efficacy remains inconclusive due to the low quality of available studies.

In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.

This review discusses valproic acid as a common antiseizure medication associated with alopecia and highlights the need for its inclusion in relevant medical guides, without presenting new clinical findings.

In this case study, a three-year-old Labrador with canine atopic dermatitis showed significant improvement in pruritus and skin lesions after treatment with oclacitinib and supportive therapy over a one-month follow-up.

Baricitinib helps regrow hair in teens with severe alopecia areata.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.